🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to the Transposon data presentations at the 2024 Annual NEALS Consortium Meeting. Company will share promising results from P2 study of TPN-101 in patients with (#ALS) and/or frontotemporal dementia (#FTD). transposonrx.com/pdf/Transposon…

Congrats to the team at Nocion Therapeutics for kicking off a global, multi-center Phase 2b clinical trial of its lead development candidate, taplucanium, for the treatment of chronic #cough. Canaan's Julie Papanek Grant sits on the board. nociontx.com/nocion-therape…

Pathios Therapeutics doses 1st patient in P 1/2 trial of PTT-4256, 1st-in-class GPR65 inhibitor. Compound showed promising preclinical anti-#tumor activity and we're excited to see what plays out in the #clinic. pathiostherapeutics.com/pathios-therap…

Transposon expands pipeline into #oncology with acquisition of novel #nucleoside #chemotherapeutics. Builds upon leadership in developing best-in-class, nucleoside reverse transcriptase inhibitors for #neurodegenerative and #autoimmunediseases. transposonrx.com/pdf/Transposon…

Great to see Rondo Therapeutics teaming up with Eli Lilly and Company in a collaboration to develop novel #CD28 #bispecific #antibodies for solid #tumors. Congrats to the Rondo team, including Canaan's Nina Kjellson, who sits on the board. businesswire.com/news/home/2024…

Alphina Therapeutics appoints Marc Damelin as CSO to help guide best-in-class #NAMPTinhibitor program toward the clinic. Canaan's Colleen Cuffaro sits on Alphina's board of directors. Read the company’s press release on Dr. Damelin's appointment here: alphinatx.com/news-press/

We couldn't be more excited to announce Kumar as our newest venture partner at Canaan! A visionary technologist and seasoned software leader who exemplifies our values, Kumar will be an asset to our team. Read more on the news here: canaan.com/latest/kumar-s…

Congrats to our newest portfolio co. WiseLayer on today's funding milestone! WiseLayer's AI agents tackle essential yet time-consuming financial + accounting tasks so companies can redirect focus toward growth + innovation. Read more here: canaan.com/latest/wiselay…

Positive topline data from Qlaris Bio in 2 P2 clinical trials of QLS-111. Treatment demonstrated impressive reductions in intraocular pressure (#IOP) and encouraging safety and tolerability. Canaan’s Wende Hutton sits on its board. #glaucoma #ocular qlaris.bio/qlaris-bio-ann…

🚀 I'm thrilled to announce Valid has raised $5.5M led by Canaan, with participation from Neo, Jventures, Steve Huffman (Reddit CEO), and Scott Banister (inventor of search ads). With this injection of capital, we are accelerating towards building the infinitely

Halda Therapeutics doses 1st patient in P 1/2 trial of HLD-0915 in metastatic castration-resistant #prostate #cancer.  Big step for novel small molecule #RIPTAC modality. Canaan's Tim Shannon chairs the company’s board. haldatx.com/halda-therapeu…

Canaan’s Dana warren and Brendan Dickinson shared with Fintech Nexus how startups can navigate uncertainty, stay capital-efficient, and turn volatility into opportunity. Read more here: fintechnexus.com/early-stage-fo…

With $35M of new funding, Vivace Therapeutics is full speed ahead on developing its first-in-class #TEAD inhibitor, VT3989. Plans to move into P3 trial in #mesothelioma. We're proud to have participated in the Series D. Tim Shannon sits on the board. prnewswire.com/news-releases/…

Pathios continues to build its leadership team. Just four months after initiating its first-in-human clinical trial of its lead #GPR65inhibitor, the company has added a chief medical officer. Welcome Dr. Sumeet Ambarkhane. #immunooncology #cancer pathiostherapeutics.com/pathios-therap…

ThirtyFiveBio closes bridge round with new strategic investment from AbbVie Ventures and continued support from Canaan. Funds will support first-in-class #GPR35 inhibition approach to treating #GI diseases including digestive tract #colitis and #cancers. 30fivebio.com/thirtyfivebio-…

Halda Therapeutics adds new member to leadership team. Appointment of Dr. Eyal Attar as CMO will serve company well as it advances its #RIPTAC small molecule platform through clinical trials. #cancer Canaan's Tim Shannon chairs the company’s board. haldatx.com/halda-therapeu…

Canaan portfolio company Rondo Therapeutics signs #antibody discovery collaboration with AbTherx. Will leverage AbTherx's platform to deliver therapeutic #antibodies that Rondo has the right to develop & commercialize. Our Nina Kjellson sits on Rondo board. accessnewswire.com/newsroom/en/bi…

Nocion Therapeutics appoints Dr. Matthew Frankel as chief medical officer. Brings significant executive management experience in therapeutic development as taplucainium P2b trial for chronic #cough continues. Canaan's Julie Papanek Grant sits on the board. nociontx.com/nocion-therape…

Transposons' TPN-101 selected for inclusion in the innovative P 2/3 Healey #ALS Platform Trial being run at the Sean M. Healey & AMG Center for ALS at Mass General Hospital and in partnership with NEALS Consortium. Read the company’s press release here: transposonrx.com/pdf/Transposon…

New Canaan portfolio co launch: Vima Therapeutics. $60M Series A round to support development of VIM042, the first-oral therapy for #dystonia and related #movement #disorders. Our own Julie Papanek Grant sits sits on BOD. vimatx.com/news/